Skip to main content

Table 2 Radiological evaluation by computed tomography after neoadjuvant chemotherapy

From: The validity of neoadjuvant chemotherapy with paclitaxel plus S-1 is not inferior to that of SOX regimen for locally advanced gastric cancer: an observational study

Parameter

SOX group

PTXS group

P value

T stage (post-NAC)

  

0.088

 T1

1 (1.3)

0 (0.0)

 

 T2

2 (2.6)

0 (0.0)

 

 T3

33 (42.9)

18 (69.2)

 

 T4

41 (53.2)

8 (30.8)

 

N stage (post-NAC)

  

0.370

 N0

5 (6.5)

4 (15.4)

 

 N1

50 (64.9)

14 (53.8)

 

 N2

20 (26.0)

6 (23.1)

 

 N3

2 (2.6)

2 (7.7)

 

TNM stage (post-NAC)

  

0.190

 II

33 (42.9)

15 (57.7)

 

 III

44 (57.1)

11 (42.3)

 

Response rate

  

0.188

 CR

0 (0.0)

0 (0.0)

 

 PR

33 (42.9)

9 (34.6)

 

 SD

40 (51.9)

15 (57.7)

 

 PD

4 (5.2)

2 (7.7)

 

DCR (CR + PR + SD)

73 (94.8)

24 (92.3)

0.641

Descending stage rate

23 (29.9)

10 (38.5)

0.417

  1. NAC Neoadjuvant chemotherapy, SOX Oxaliplatin plus S-1, PTXS Paclitaxel plus S-1, PR Partial response, SD Stable disease, PD Progressive disease, DCR Disease control rate